Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1984 Aug;43(4):653–655. doi: 10.1136/ard.43.4.653

Anaplastic myeloma in systemic lupus erythematosus.

R C Butler, S M Thomas, J M Thompson, A C Keat
PMCID: PMC1001430  PMID: 6476924

Abstract

We describe a patient with systemic lupus erythematosus who developed an unusual form of anaplastic myeloma. Possible relationships between the two disease, and the role played by immunosuppressive therapy, are discussed.

Full text

PDF
653

Images in this article

654Image
on p.654

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Caldwell D. S. Musculoskeletal syndromes associated with malignancy. Semin Arthritis Rheum. 1981 Feb;10(3):198–223. doi: 10.1016/s0049-0172(81)80003-0. [DOI] [PubMed] [Google Scholar]
  2. Canoso J. J., Cohen A. S. Malignancy in a series of 70 patients with systemic lupus erythematosus. Arthritis Rheum. 1974 Jul-Aug;17(4):383–390. doi: 10.1002/art.1780170407. [DOI] [PubMed] [Google Scholar]
  3. Cohen S. R., Landing B. H., Isaacs H., King K. K., Hanson V. Solitary plasmacytoma of the larynx and upper trachea associated with systemic lupus erythematosus. Ann Otol Rhinol Laryngol Suppl. 1978 Sep-Oct;87(5 Pt 2 Suppl 52):11–14. doi: 10.1177/00034894780870s503. [DOI] [PubMed] [Google Scholar]
  4. Fauci A. S., Steinberg A. D., Haynes B. F., Whalen G. Immunoregulatory aberrations in systemic lupus erythematosus. J Immunol. 1978 Oct;121(4):1473–1479. [PubMed] [Google Scholar]
  5. Foucar K., Raber M., Foucar E., Barlogie B., Sandler C. M., Alexanian R. Anaplastic myeloma with massive extramedullary involvement. Report of two cases. Cancer. 1983 Jan 1;51(1):166–174. doi: 10.1002/1097-0142(19830101)51:1<166::aid-cncr2820510132>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  6. HAYES D. W., BENNETT W. A., HECK F. J. Extramedullary lesions in multiple myeloma; review of literature and pathologic studies. AMA Arch Pathol. 1952 Mar;53(3):262–272. [PubMed] [Google Scholar]
  7. Jordan E., Burnstein S. L., Calabro J. J., Henderson E. S. Multiple myeloma complicating the course of seronegative systemic lupus erythematosus. Arthritis Rheum. 1978 Mar;21(2):260–265. doi: 10.1002/art.1780210215. [DOI] [PubMed] [Google Scholar]
  8. Kaufman D. B. Natural killer augmentation in systemic lupus erythematosus via a soluble mediator derived from human lymphocytes. Arthritis Rheum. 1982 May;25(5):562–567. doi: 10.1002/art.1780250511. [DOI] [PubMed] [Google Scholar]
  9. Kinlen L. J., Sheil A. G., Peto J., Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J. 1979 Dec 8;2(6203):1461–1466. doi: 10.1136/bmj.2.6203.1461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lewis R. B., Castor C. W., Knisley R. E., Bole G. G. Frequency of neoplasia in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 1976 Nov-Dec;19(6):1256–1260. doi: 10.1002/art.1780190605. [DOI] [PubMed] [Google Scholar]
  11. Lynch R. G., Rohrer J. W., Odermatt B., Gebel H. M., Autry J. R., Hoover R. G. Immunoregulation of murine myeloma cell growth and differentiation: a monoclonal model of B cell differentiation. Immunol Rev. 1979;48:45–80. doi: 10.1111/j.1600-065x.1979.tb00298.x. [DOI] [PubMed] [Google Scholar]
  12. Neuberg R. Immunosuppression and plasmocytoma of the cervix. J Obstet Gynaecol Br Commonw. 1974 Feb;81(2):165–167. doi: 10.1111/j.1471-0528.1974.tb00438.x. [DOI] [PubMed] [Google Scholar]
  13. Suchman A. L., Coleman M., Mouradian J. A., Wolf D. J., Saletan S. Aggressive plasma cell myeloma. A terminal phase. Arch Intern Med. 1981 Sep;141(10):1315–1320. [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES